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Hepatocellular carcinoma arises commonly on the background of liver cirrhosis. 
Patients presenting with clinical symptoms have advanced stage and often are unsuit-
able for curative therapies. Diagnosis of hepatocellular carcinoma is commonly 
performed by multiphase computed tomography (CT) and / or magnetic resonance 
imag¬ing scans (MRI). Contrast enhanced ultrasound and MRI with hepatobiliary 
contrast agents are better in characterizing small lesions. Tumor markers play an 
adjunct role in diagnosis. For HCC in cirrhotic liver biopsy is seldom required and 
diagnosis is based on typical imaging features of non-rim arterial phase hyperenhance-
ment and washout on delayed phase and pseudocapsule appearance. This is due to 
differential blood supply of liver parenchyma, regenerative nodules and tumor. Biopsy 
is only required in noncirrhotic liver, vascular liver diseases, atypical imaging features. 
Surveillance programs involving high risk groups can help in early detection of lesions 
which are amenable for curative therapies. Biannual ultrasound with or without alfa 
fetoprotein are commonly used surveillance tests. Multidisciplinary teams provide 
platform for care coordination, reassessments of clinical course, and fine changes in 
treatment plans required for management of this complex group of patients.
Keywords: hepatocellular carcinoma, surveillance, tumor markers, multiphase 
computed tomography, multiphase magnetic resonance imaging, LI-RADS, 
multidisciplinary team
1. Introduction
Hepatocellular carcinoma (HCC) is the most common primary malignant tumor 
of liver. It is sixth most commonly diagnosed cancer and fourth leading cause of can-
cer related mortality worldwide [1]. Most cases are diagnosed late in course of disease 
so that curative treatments could not be offered to such patients and hence incidence 
to mortality ratio for HCC approaches 1 [2]. Incidence of HCC is likely to increase due 
to increase in population and aging, as well as changing distribution of risk factors 
like obesity, hepatitis B and C virus infection and alcohol consumption [3]. Diagnosis 
at early stages and implementing surveillance programs in high risk population may 
reduce mortality [3]. This chapter focuses on diagnosis and surveillance for HCC.
2. Diagnosis of hepatocellular carcinoma
Diagnosis of hepatocellular carcinoma is primarily based on imaging with mul-
tiphase computed tomography (CT) scan and/or multiphase magnetic resonance 
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imaging (MRI) scan. Like in other cancers, biopsy is required in selective cases 
where there is diagnostic dilemma. HCC usually becomes symptomatic only in 
advanced stages of the disease hence clinical features are seldom useful for the diag-
nosis of disease. Tumor markers are useful blood test in supporting diagnosis and 
prognostication of most of HCC however, they have their own limitations in early 
diagnosis of HCC. This section throws light on clinical features, imaging investiga-
tions and tumor markers and there role in diagnosis of hepatocellular carcinoma.
2.1 Clinical features of HCC
Early HCC are asymptomatic and are usually picked up during surveillance 
imaging. Classic clinical triad of right upper quadrant abdominal pain, palpable 
lump and weight loss is noted in 90% of the symptomatic patients [4]. New onset 
of abdominal pain and abdominal distension due to ascites are common in patients 
with underlying liver cirrhosis [5, 6]. Rapid worsening of portal hypertension 
indicates invasion of portal vein by tumor leading to tumor thrombosis [6]. 
Generalized weakness, anorexia and weight loss are common symptoms noted 
in 90%, 74% and 55% patients respectively [7]. Catastrophic presentation in the 
form of tumor rupture, hemoperitoneum and shock occurs in 3–15% of cases 
[8]. Hepatomegaly with irregular or nodular surface is common finding in nearly 
84% cases [7]. Arterial bruit is present in minority of cases (2.6%) [9]. Ascites 
in HCC is most commonly due to underlying decompensated cirrhosis or due to 
tumor invasion of hepatic veins, portal vein or peritoneum and is often hemor-
rhagic [9]. Paraneoplastic manifestations of HCC include type B hypoglycemia 
due to increased production of insulin like growth factors by tumor, hypercal-
cemia, hypertension, carcinoid syndrome, clubbing, polycythemia, porphyria, 
thyrotoxicosis, migratory thrombophlebitis, watery diarrhea, sexual changes like 
 feminization, gynecomastia [9].
2.2 Imaging diagnosis of hepatocellular carcinoma
Almost 90% of HCC develop on the background cirrhotic liver [10]. 
Regenerative nodules form in cirrhotic livers obtain majority of blood supply from 
portal vein, like the normal liver parenchyma. As the nodule progresses from regen-
erative to dysplastic and then into HCC, there is shift in blood supply from portal 
vein to hepatic artery [10]. Hence HCC obtains majority of the blood supply from 
hepatic artery. This forms the basis of diagnosis of HCC by non-invasive methods 
using multiphase computed tomography scan (CT) and magnetic resonance imag-
ing (MRI). Radiology forms the cornerstone in diagnosis of HCC in cirrhotic liver. 
Non-invasive methods are applied to nodule ≥1 cm in cirrhotic liver due to high 
pretest probability [10].
Technical details related to machine, required images and additional images to 
be taken while evaluating liver nodule are mentioned in Table 1.
2.2.1  Typical appearance of hepatocellular carcinoma in cirrhotic liver on 
multiphase CT or MRI scans include
1. Non-rim arterial phase hyperenhancement AND
2. Non-rim washout in portal venous phase
3. Enhancing capsule appearance in portal venous phase or delayed venous phase
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4. Increase in size of mass > 50% in <6 months measured in same phase sequence 
and plane (if possible). To measure the size of lesion largest outer edge to outer 
edge dimensions should be taken.
5. Ancillary features for diagnosis of HCC include hyperintensity on T2-weighted 
MRI, hyperintensity on diffusion-weighted MRI, intra-lesional fat, lesional 
iron sparing, corona enhancement, presence of capsule, mosaic architecture, 
nodule-in-nodule architecture, intralesional hemorrhage however, these 
features do not have specificity of 100% and do not allow conclusive diagno-
sis of HCC.
2.2.2  Comparison of multiphase CT and MRI with extracellular contrast agents 
performance in detecting HCC
Table 2 shows comparative performance of multiphase CT and MRI in HCC 
with various sizes [12].
For all sizes and tumors with <1 cm MRI with extracellular contrast agents 
appears to be more sensitive than CT scan with comparable specificity and diag-
nostic odds. Hence for small lesions MRI with extracellular contrast agents may 
be preferred modality over CT scan. Having said this availability, cost, longer scan 
times, more technical complexities, expertise, several patient factors like ascites, 
difficulty in breath holding, claustrophobia may limit its use as the first investiga-
tion for evaluation of liver lesion in cirrhotic patients. CT scan on the other had is 
technically relatively simple, less number and short duration of sequences, widely 
available and less costly than MRI. However, radiation exposure is the disadvantage 
of the CT scan. Hence multiple factors like availability, cost, patient related factors, 
tumor size, radiation are necessary to be considered to choose between CT scan and 
MRI as first investigation for evaluation of liver lesion [12].
Technical details Multiphase CT scan MRI scan
Machine 
specifications
• Multidetector CT with more than 8 
detector rows
• Slice thickness 3 mm
• Injection rate 4 milliliter/second
• 1.5 T or 3 T
• Torso phased array coil
Required images • Non-contrast
• Arterial phase at 30 seconds with 
bolus tracking
• Venous phase at 65 seconds
• Delayed phase at 240 seconds
• Unenhanced T1 weighted in phased 
and opposed phase imaging
• T2 weighted imaging (fat suppression 
per institutional preference)




• Portal venous phase




• Precontrast in patients with locore-
gional treatment




Technical details, required images and additional images to be obtained while evaluating liver space occupying 
lesion [11].
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2.2.3 Role of MRI with hepatocyte specific contrast agents in diagnosis of HCC
This technique uses Gadoxetic acid as a contrast agent. Approximately 50% of 
the administered dose is taken up by hepatocyte and excreted into the bile ducts 
and remaining half was excreted by kidneys [13]. Images are taken in two phases: 
Transitional phase taken at 2–5 minutes after contrast agent and hepatobiliary 
phase taken after 20 minutes of contrast injection [13]. Lesions with functional 
hepatocytes take up the contrast in hepatobiliary phase and appear hyperintense. 
Those without functional hepatocytes like high grade dysplastic nodules or HCC 
do not take the contrast in hepatobiliary phase and appear hypointense compared 
to background liver parenchyma [13]. These early HCC or high grade dysplastic 
nodules may not show typical arterial hyperenhancement resulting in missing some 
of the early HCC lesions. Addition of hepatobiliary phase to conventional dynamic 
MRI sequences increases likelihood of identifying malignant nodules and reduces 
the risk of overlooking malignant lesions [13–15]. Signal intensity of lesion on hepa-
tobiliary phase is also a prognostic factor with hypointense lesions on hepatobiliary 
phase which are non-hypervascular, non-HCC have a higher risk of progression to 
typical HCC as compared to those lesions which are iso- or hyper-intense [16, 17].
2.2.4 Role of contrast enhanced ultrasound in diagnosis of HCC
It is performed with intravenous injection of a microbubble contrast agent. 
Real-time imaging is performed continuously for the 1st minute to capture the arte-
rial phase. This is followed by intermittent scanning every 30–60 seconds for up to 
about 5 minutes to evaluate washout [11]. Typical appearance of HCC on Contrast 
enhanced ultrasound (CEUS) shows non rim arterial phase hyperenhancement and 
washout in delayed phase >60 seconds to differentiate it from mass forming chol-
angiocarcinoma which show early washout. It requires expertise and cannot scan 
entire liver at a time like CT or MRI [11]. CEUS has low sensitivity for detection of 
lesion as compared to CT and MRI but has higher specificity as compared to CT and 
MRI especially for small nodules (< 20 mm) 92.9% vs. 76.8% vs. 83.2% [18]. CEUS 
as second imaging modality has highest specificity 76.8% (after MRI) and 70.7% 
(after CT) for diagnosis of HCC [19].
2.2.5 Liver imaging reporting and data system (Li-RADS)
Liver imaging reporting and data system (Li-RADS) provides standardiza-
tion for hepatocellular carcinoma (HCC) imaging. Li-RADS defines eight unique 
Tumor 
size
Sensitivity (CT vs. MRI) Specificity (CT vs. MRI) Diagnostic odds
CT vs. MRI























Comparative performance of multiphase CT and MRI in HCC with various sizes.
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diagnostic categories LR 1 to 5, LR-M for malignant but not specific for HCC, 
LR-TIV for tumor in vein, LR-TR for treated lesion, based on imaging appear-
ance that reflect the probability of HCC or malignancy with or without tumor 
in vein. Term LR-NC (non-categorizable observation) is used when observation 
that cannot be meaningfully categorized due to lack of one or more major criteria. 
LI-RADS criteria are to be applied for liver nodules in cirrhotic livers and lesion 
>1 cm. Table 3 describes the each Li-RADS category and risk of HCC and non-
HCC malignancy [11].
LI-RADS is not applicable for liver lesions in noncirrhotic liver, vascular liver 
diseases, sinusoidal obstruction syndrome, chronic inflow obstruction and heredi-
tary hemorrhagic telangiectasia.
2.2.6  Role of Fluorodeoxyglucose positron emission tomography (FDG-PET) in 
diagnosis of HCC
FDG uptake is seen only in 40% of patients with HCC, so FDG-PET scan is not 
useful for diagnosis of HCC [20]. Uptake on 18F-FDG-PET has some potential 
prognostic significance and is associated with poor prognosis, increased serum 
alpha-fetoprotein and vascular invasion. Therefore, it may facilitate the selection of 
patients for surgical resection or liver transplantation [21].
2.2.7  Diagnosis of portal vein thrombosis- tumoral vs. non-tumoral (bland 
thrombus)
Cirrhosis without HCC is associated with portal vein thrombosis with preva-
lence ranging from 1% in compensated cirrhosis to as high as 25% in patients with 
advanced liver disease requiring liver transplantation [22]. Macrovascular invasion 
of the portal vein is a major prognostic factor frequently seen in HCC. Portal vein 
thrombosis may create diagnostic dilemma in patients with cirrhosis and HCC. 
Presence of arterial phase hyperenhancement, diffusion weighted MRI with high 
b values, venous expansion with diameter > 23 mm, thrombus in continuity with 
parenchymal HCC are the findings which point towards the diagnosis of tumoral 
portal vein thrombosis [23, 24].
2.3 Pathological diagnosis of hepatocellular carcinoma
HCC diagnosis in cirrhotic liver is based on imaging criteria mentioned above. 
However biopsy is required in patients with vascular liver diseases, non-cirrhotic 
livers, inconclusive radiological investigations, elevation of CA 19.9 or carcino-
embryonic antigen (CEA) and liver lesion without HCC risk factors [24]. Samples 
for histological diagnosis of HCC can be obtained by image guided (ultrasound /
CT scan) biopsy sometimes by diagnostic laparoscopy. Resected specimens and 
explants after liver transplants need evaluation for resection margin and histologi-
cal assessment [24].
2.3.1 Gross appearance
HCC takes three forms nodular, massive or diffusely infiltrating type. Nodular 
form is often associated with liver cirrhosis. Massive form is associated with satellite 
nodules and has potential to rupture. Diffuse infiltrating type causes involvement 
of large part of liver and its vascular structures mainly portal vein, and is associated 
with poor prognosis [25].
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2.3.2 Microscopic appearance
Microscopically HCC can be well differentiated, moderately differentiated, undif-
ferentiated and progenitor cell. Most common variety is well differentiated type. It can 
Li-RADS 
category




LR-NC Observation that cannot be 
categorized into specific category 





LR-1 Benign observation with 100% 
certainty
Benign 0% 0%
LR-2 High probability of being benign 
observation. No major features, 
LR-M features, ancillary features 
favoring malignancy
Probably benign 13% 14%
LR-3 Nonmalignant and malignant 
entities each have moderate 
probability.
Nonrim APHE without any other 
major features OR
Arterial phase iso/
hypoenhancement with size 
<20 mm and ≤ 1 additional major 







LR-4 High probability of HCC but not 
100% certainty.
Non rim APHE and < 10 mm 
and ≥ 1 additional major feature
10–19 mm with capsule
>20 mm with ≥1 additional major 
feature OR
<20 mm with 2 additional major 
features
Probably HCC 74% 80%
LR-5 100% certainty of being HCC
Nonrim APHE and
10–19 mm with non-peripheral 
washout OR
10–19 mm with ≥50% size increase 
in <6 months
>20 mm with ≥1 additional feature
Definitely HCC 94% 97%
LR-TIV Presence of soft tissue in vein 









Nontargetoid mass not meeting 











LI-RADS criteria with description of terminologies, risk of overall malignancy and risk of HCC.  
[APHE – Arterial phase hyperenhancement, TIV- tumor in vein].
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be of trabecular type or acinar type (pseudoglandular type). Malignant hepatocytes 
are polygonal with large hyperchromatic nuclei. Bile production is present. Moderately 
differentiated HCC can be of solid, scirrhous, sarcomatoid and clear cell varieties. 
Solid type tumor shows small hepatocytes with areas of necrosis, inconspicuous 
fibrous tissue and absent bile production. In scirrhous variety abundant connective 
tissue stroma is noted separating hepatocytes. Clear cell variety has cells having high 
glycogen content. Undifferentiated HCC has pleomorphic cells with variable sized 
nuclei. Progenitor cell HCC have their origin from stem cells of liver. These tumors 
may appear similar to HCC or mixed cholangiohepatocellular carcinoma [25]. On 
biopsy specimens differentiation of small HCC from high grade dysplastic nodules is 
challenging. Diagnosis of HCC needs to be supplemented with three marker panel as 
recommended by International Consensus Group of Hepatocellular Neoplasia and the 
World Health Organization. This is because features of interstitial and vascular inva-
sion can be missed on biopsy specimens. Combination of HSP70 (HSPA7), glypican 
3 (GPC3), and glutamine synthetase (GS) has sensitivity and specificity of 72% and 
100%, respectively in surgically resected specimens and its specificity is validated in 
biopsy specimens [26, 27]. Several immunohistochemical markers useful in diagnosis 
of hepatocellular carcinoma include Arginase-1 which is most sensitive and specific 
marker for hepatocellular differentiation. Hepatocyte paraffin-1 (Hep Par-1) has both 
sensitivity and specificity greater than 80% for HCC. Polyclonal carcinoembryonic 
antigen (pCEA) shows typical canalicular pattern and has sensitivity of 92% and 88% 
for well differentiated and moderately differentiated HCC [28].
HCC is heterogenous tumor in pathogenesis, behavior, phenotype and has dif-
ferent genetic signatures as described by recent studies. As mentioned above several 
different subtypes are described. 5th edition of world health organization classifica-
tion of digestive system tumors integrates histopathologic features and molecular 
signatures of these tumors. Table 4 shows morphological features, molecular 
signatures of different HCC subtypes as per 5th Edition of WHO Classification of 
Digestive system tumors [29, 30].
2.3.3 Risks associated with biopsy of the lesion
Biopsy is associated with risk of bleeding in 3–4% cases and severe bleeding 
requiring transfusion in 0.5% cases [31]. Risk of needle track seeding of tumor cells 
is about 2.7% [32]. Sampling errors can occur for small lesions <2 cm [33].
2.4 Role of tumor markers in diagnosis of HCC
Tumor markers are the substances which can be measured in cells, tissues, body 
fluids, indicate presence of cancer and help in prognostication. Ideal tumor marker 
should be highly sensitive and specific so as to diagnose lesions early HCC. Alfa 
fetoprotein (AFP) is used since long time for surveillance and diagnosis of hepa-
tocellular carcinoma [34]. Now with identification of new molecular signatures, 
our understanding of pathological processes involved in HCC is improved leading 
development of newer biomarkers. This section will through light on old and new 
tumor markers and their utility in diagnosis of HCC [34].
2.4.1 Alfa fetoprotein (AFP)
AFP is a glycoprotein produced by fetal liver. After birth levels of AFP fall and its 
synthesis is repressed in adult life. It is expressed under some pathological conditions 
like chronic liver disease, cirrhosis, HCC, germ cell tumors and cholangiocarcinoma 
[35]. It is the most extensively studied biomarker for surveillance and diagnosis of 
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HCC. AFP is elevated in nearly 70% patients with HCC. When cut-off value of 20 ng/
ml is used AFP has sensitivity of 59.9% and specificity of 93% while at the cut-off 
value of 200 ng/ml sensitivity drops to 22% and specificity of 100% [35, 36]. AFP 
can be falsely elevated in patients with viral infections like hepatitis B and C. Positive 
predictive value of AFP in diagnosing HCC in patients with viral etiologies and 
non-viral etiologies was 70% vs. 94% in one study using cut-off of 20 ng/ml [34]. 
AFP also has prognostic significance with values ≥400 ng/ml have higher tumor 
burden, bilobar involvement, tumoral portal vein thrombosis and diffuse and mas-
sive variety of tumors [35]. Limitations of AFP measurement include false negative in 
small HCC and 30% of large tumors do not have elevated levels [35]. False positive in 
chronic liver disease, cirrhosis, HCC, germ cell tumors and cholangiocarcinoma [34, 
35]. AFP-L3 glycoform of AFP is detected in approximately 35% of <3 m size HCC. 
Cut-off level of 15% has sensitivities ranging from 75%–96.9% and specificities of 
90–92% [35]. Higher levels of AFP-L3 are associated with worse liver function, poor 
histology and large tumor mass and portal vein invasion [35].
2.4.2 Glypican-3
It is proteoglycan in plasma membrane. It produced by tumor cells but not 
elevated in non-HCC liver diseases. It can be detected in 40–53% of HCC patients 
and 33% of HCC patients with negative for both AFP and PIVKA-II. Addition of 
Glypican-3 measurements to AFP improves sensitivity from 50–72% [34, 35].
Variant Histopathology Molecular signature Comments





Less often vascular invasion 
or satellite nodules. Prognosis 
similar to conventional HCC
Clear cell >80% cells 
demonstrates clear 
cytoplasm due to 
glycogen.
Not known Slightly better prognosis 
compared to conventional 
HCC. Needs differentiation 
from clear cell type of renal 
cell carcinoma.




Associated with HBV 
infection, vascular invasion, 
poor differentiation, high 
alfa-fetoprotein.
Scirrhous Tumor cells mixed 






Large tumors, vascular 
invasion, infiltrative growth.
Chromophobe Cells have clear 
cytoplasm, focal 





Prognosis similar to 
conventional HCC.







Elevated leucocyte count, 
interleukin-6. Poor prognosis.
Lymphocyte rich Lymphocytic 
infiltration of tumor.
Not known. Favorable outcome to 
conventional HCC.
Table 4. 
Shows morphological features, molecular signatures of different HCC subtypes as per 5th edition of WHO 
classification of digestive system tumors.
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2.4.3  Des-gamma-carboxyprothrombin or protein induced by vitamin K absence 
or antagonist II (PIVKA-II)
It is abnormal product from liver carboxylation disturbance during the forma-
tion of thrombogen [34, 35]. It is overproduced in HCC patients. Sensitivity and 
specificity of PIVKA-II at the cut-off level 40 mAU/ml is 51.7% and 86.7% while 
at the cut-off value of 125 mAU/mL in discriminating HCC from nonmalignant 
hepatopathy sensitivities and specificities were 89% and 86.7% [37, 38]. In com-
bination AFP-L3, AFP and DCP achieved 60.6% sensitivity and 100% specificity 
while DCP combined with AFP alone increased sensitivity from 65–87%, but 
specificity dropped from 84–69% [39, 40]. Japanese clinical guidelines recommend 
the combined use of PIVKA-II and AFP for the diagnosis of HCC, management of 
high-risk population, and prognosis of anticancer treatment [41].
2.4.4 Long noncoding RNAs (Inc RNAs)
Recent evidences have shown that long noncoding RNAs (lncRNAs) are involved 
in cancer diagnosis and prognosis. Pooled sensitivity, specificity, positive likelihood 
ratio (PLR), negative likelihood ratio (NLR), diagnostic odds ratio (DOR), and 
AUC for lncRNAs in the diagnosis of HCC were 0.83, 0.80, 4.2, 0.21, 20, and 0.88, 
respectively [42].
Table 5 summarizes newer biomarkers under evaluation for diagnosis of HCC.
2.5 Fibrolamellar hepatocellular carcinoma (FL-HCC)
Rare variant of HCC accounting for only 1% cases. In contrast to conventional 
HCC, FL-HCC is common in young patients aged <40 years, occurs in normal liver 
and has normal AFP levels [53]. FL-HCC is chromosomally stable tumor and displays 
genomic homogeneity in contrast to conventional HCC. Mutations in AFP, TP53 
beta-catenin and surviving are not seen in FL-HCC, however increased expression 
of anterior gradient-2, CD133, CD44 and nuclear factor-kB pathway are seen in 
FL-HCC. Chromosomal imbalances involving chromosomes 1, 7 and 8 are noted in 
aggressive FL-HCC [54–56]. FL-HCC is typically large tan colored well-circumscribed 
firm mass without underlying chronic liver disease or cirrhosis. Central stellate 
scar is seen in 75% cases. Microscopically it is composed of cluster or sheets of large 
polygonal or spindle shaped cells with eosinophilic cytoplasm and prominent nuclei. 
Fibrous stroma is seen around the tumor cells. It has capsule and central scar [57, 58]. 
On immunohistochemistry it shows hepatocyte paraffin 1, CK7, CD133, CD44, α-1-
antitrypsin, fibrinogen, C-reactive protein, carcinoembryonic antigen and copper 
[55, 59]. Patient presents with abdominal pain, malaise, weight loss and abdominal 
lump [57]. On ultrasound FL-HCC has no specific features [60]. On computed 
tomography scan tumors are well defined with lobulated outline. It has hypodense 
large >2 cm central scar and radiating fibrotic bands are more common. Central scar 
may show calcification. On contrast enhancement in arterial phase it shows heteroge-
nous hyperattenuation. On the portal venous phase and delayed phase, approximately 
50% of fibrolamellar HCCs become isoattenuating to liver. However, they may also be 
hyperattenuating (36%) or hypoattenuating (16%). Central scar may show delayed 
enhancement in 25–65% cases. Venous and biliary obstruction is rare [60]. On MRI, 
FL-HCC is hypointense on T1 imaging and hyperintense on T2 images. Central scar is 
hypointense on T1 and T2 weighted images. On contrast injection, it shows heterog-
enous enhancement which becomes iso or hypointense in delayed phase [60]. Nodal 
metastasis occur in 50–65% of FL-HCC and commonly occur in hepatoduodenal 
ligament and hepatic hilum. Cornerstone for treatment is surgical resection with 
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adequate lymph node dissection. The 5 year overall survival rate after partial hepatec-
tomy was 70%. Radioembolization using 90Y is helpful in unresectable FL-HCC. Liver 
transplantation is therapeutic option in selected patients [60, 61].
2.6 Diagnosis of HCC in noncirrhotic liver
About 10% HCC can occur in noncirrhotic liver. Risk factors include alcohol 
(21%), chronic hepatitis B(30.60%), chronic hepatitis C infection (14.36%), 
diabetes (40%), family history (13.85%) and cryptogenic (39%). Other risk factors 
include aflatoxin B, metabolic liver diseases, chemical and industrial carcinogens 
like vinyl chloride. HCC in noncirrhotic liver present as advanced disease, larger in 
size [62]. Male to female ratio is 2:1. Hepatomegaly, abdominal pain, malaise, weight 
loss and anorexia are common presenting features [62, 63]. On ultrasound, lesion 
can be hypoechoic, hyperechoic due to intralesional fat or mixed echogenicity due 
to necrosis. On unenhanced CT, lesions appear as hypodense circumscribed masses. 
Few of them show calcifications, hemorrhagic areas and necrosis. On contrast injec-
tion, it does show arterial phase hyperenhancement and washout in delayed phase 
but specificity is lower as other lesions like hepatocellular adenoma and hypervas-
cular metastasis. On MRI these tumors have variable T1 and T2 weighted images 
depending on degree of fat, necrosis and fibrosis. On contrast injection, features are 




1 Serum Gamma-glutamyl 
transferase II isoenzyme 
[43]
74% for all HCC and 34% for small HCC. In combination with 
AFP, PIVKA-II sensitivity may be improved.
2 Alpha-I-fucosidase [44] Activity increases in HCC patients. Sensitivity and specificity 
at 870 nmol/ml per hour is 81.7% and 70.7% respectively
3 Alfa-fetoprotein mRNA 
[45, 46]
Serum AFP mRNA detected by reverse-transcription 
polymerase chain reaction (RTPCR) is correlated with portal 
vein thrombosis, number of nodules of tumor, tumor diameter, 
stage and post-operative recurrence.
4 Human telomerase 
reverse transcriptase 
mRNA (hTERT) [47, 48]
It has sensitivity and specificity of 88.2% and 70% and 
levels correlate with AFP concentration, tumor size, tumor 
differentiation.
5 Vascular endothelial 
growth factor(VEGF) 
[49]
Serum VEGF levels per platelet count are increased >1.4 
picogram/106 in patients with HCC and correlate with stage, 
portal vein thrombosis, response to therapy and survival.
6 Interleukin-8 [50] It is chemokine having direct effect on tumor cells, 
angiogenesis, tumor migration. Serum levels are significantly 
elevated in HCC patients compared to healthy adults and 
correlate with tumor size, venous invasion, advanced stage, 
absence of capsule and poor prognosis
7 Transforming growth 
factor-beta 1 [51]
Serum levels elevated in HCC. At cut-off 800 pg./ml sensitivity 
and specificity is 68% and 95%.
8 Tumor-specific growth 
factor (TSGF) [52]
Serum TSGF reflects the existence of tumor. It has been 
indicated that TSGF can be used as a diagnostic marker in 
detecting HCC, and its sensitivity can reach 82% at the cut-off 
value of 62 U/mL. With other markers like AFP, ferritin 
sensitivity and specificity can reach up to >90%
Table 5. 
Summary of new tumor markers in HCC.
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3. Surveillance for hepatocellular carcinoma
Surveillance is defined as periodic application of diagnostic test to individuals 
who have specific risk factors for disease. Surveillance depends on the incidence of 
the surveyed disease in the target population, the availability of efficient diagnostic 
test(s) at bearable costs and acceptability for the target population, and the avail-
ability of treatments and their effectiveness if disease is diagnosed early in course 
of disease. Primary objective of surveillance program is early diagnosis of disease so 
that curative treatments can be offered to the patients [64].
3.1 Target population for surveillance
While deciding the appropriate population it is necessary to consider incidence 
of HCC in the population, probability that curative therapies can be offered to the 
patients who are diagnosed as having the disease and cost effectiveness of surveil-
lance. In case of HCC, application of curative therapies not only depend on extent 
of tumor but also on underlying liver function. Hence appropriate patients should 
be enrolled in the surveillance program [3, 24].
3.1.1 Cirrhotic patients
Nearly 90% HCC develop on the background of cirrhosis of liver. The annual 
incidence of HCC is 2.0–6.6% in patients with cirrhosis [24]. Cost-effectiveness 
studies in western patients have shown that surveillance for HCC would be benefi-
cial if the incidence is 1.5%/year or greater, irrespective of etiology of cirrhosis [65]. 
However, advanced cirrhosis with Child score C or Child score B with gross ascites, 
hepatorenal syndrome, clinical jaundice do not qualify for curative therapies for 
HCC and do not warrant surveillance unless they are considered for liver transplan-
tation. Child A cirrhotic patients or those decompensated cirrhotic patients who 
are listed for liver transplant warrant surveillance as diagnosis of HCC modifies the 
priority and decision to transplant [66–68].
3.1.2 Noncirrhotic patients
HCC can develop in noncirrhotic liver in patients infected with hepatitis B virus. 
The risk varies with geographical distribution and is higher in Asia and Africa than 
Western countries. Higher levels of HBV replication, age and gender (males higher than 
females) are the risk factors for development of HCC which is lower than cirrhotic but 
definitely higher than general population [69, 70]. In a cohort study of males belonging 
to multiple race and age-groups, risk of HCC was highest among Asian Pacific Islanders, 
followed by whites and African Americans. Also, regardless of race, annual incidence 
of HCC was more than 0.2% for all patients older than 40 years with high levels of 
alanine aminotransferase [71]. A similar HCC incidence rate of 0.2 per 100 person-
years has been observed in inactive carriers with chronic HBV infection from East Asian 
countries. Asian females >50 years of age and patients with family history of HCC are 
also at increased risk of HCC. Hence, surveillance should be offered in the above subset 
of patients as these patients are noncirrhotic with preserved liver function and fit for 
curative resection for HCC [66, 67]. Patients with chronic hepatitis B on therapy with 
advanced fibrosis or cirrhosis at baseline should also be enrolled under surveillance 
program [72, 73]. Various scoring systems are available which can help in stratifying the 
patients based on risk of HCC and those with significant risk should be offered surveil-
lance [74]. Examples of such scoring systems include GAG-HCC score, LSM-HCC score, 
PAGE-B score, REACH-B score. REVEAL risk model [74].
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Patients with chronic hepatitis C infection with bridging fibrosis are at increased 
risk of development of HCC. Transition from advanced fibrosis to cirrhosis cannot 
be accurately determined [75]. Several studies show that liver stiffness assessment 
performed by transient elastography correlates with risk of development of HCC 
[76, 77]. Hence these patients warrant surveillance for HCC. Patients with chronic 
HCV infection previously treated, who have achieved sustained virological response 
but had advanced fibrosis or cirrhosis need HCC surveillance [74].
Prevalence of nonalcoholic fatty liver disease (NAFLD) is increasing in all part 
of the world. Nonalcoholic steatohepatitis (NASH) is associated with morbidity and 
mortality due to cirrhosis and its complications and development of HCC [3]. Similar 
to cirrhotic patients with other etiologies, patients with NASH cirrhosis should be 
included in surveillance program. A systematic review and metanalysis of studies on 
HCC in noncirrhotic NASH subjects showed that these subjects were at greater odds 
of developing HCC than non-cirrhotic subjects of other etiologies (OR 2.61, 95% CI 
1.27–5.35, P = 0.009) [78]. The incidence of HCC in patients with non-advanced fibrosis 
is expected to be insufficiently high to deserve universal surveillance, given the large 
prevalence of NAFLD in the general population [79]. American society of gastroenter-
ology clinical practice update on screening and surveillance of HCC in NAFLD suggest 
to use two noninvasive tests to assess level of fibrosis [79]. Those patients with signifi-
cant fibrosis on both tests to be enrolled in the screening program. Genetic studies have 
shown the presence of the PNPLA3 risk allele is increased in those NAFLD with HCC. 
However limited availability of the test restricts its use in clinical practice [79].
Patients with Wilson’s disease, autoimmune liver disease and alpha 1- antitrypsin 
deficiency have lower risk of developing HCC unless cirrhosis is developed. Hence 
routine surveillance is not recommended [24].
3.2 Surveillance tests
Surveillance tests should be sensitive, easily available to large population, 
less costly, safe, acceptable to the people and permits early diagnosis of disease. 
Surveillance tests used for HCC surveillance can be classified as radiological, 
serological or combination of both. Section 2.2 and 2.4 describe imaging and tumor 
markers, their sensitivity, specificity and accuracy.
3.2.1 Radiologic surveillance tests
Ultrasonography (USG) of liver is the most commonly used method for surveil-
lance. It is non-invasive, relatively inexpensive, easily available and without any 
associated risk of radiation. It has the sensitivity of 84% for any stage HCC and 63% 
for early-stage HCC [80]. In patients with cirrhosis, USG may have a suboptimal 
performance due to the presence of fibrous septa and regenerative nodules, which 
appear as a coarse pattern on ultrasound and may mask the presence of a small 
tumor. In a meta-analysis, the sensitivity and specificity of USG for detection of 
HCC at any stage were 84% (95% CI, 76–92%) and 91% (95% CI, 86–94%), respec-
tively, but, the pooled sensitivity of ultrasound was only 47% (95% CI, 33–61%) 
for detection of early-stage HCC [81]. Hence, it is recommended that USG of liver 
for HCC surveillance should be done by an expert radiologist. Compared to ultra-
sonography, computed tomography and MRI had better sensitivity and specificity 
for diagnosis of early HCC (Refer to Section 2.2 for details). However use of radia-
tion, complex imaging techniques, availability, cost of imaging are the important 
limiting factors. While comparing 6-monthly USG and yearly triphasic CT for HCC 
surveillance, it was found that biannual ultrasound was more sensitive (71.4%) 
when compared to CT (66.7%) with lower overall cost [82].
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3.2.2 Serological tests
Serological test for early diagnosis of HCC include AFP, PIVKA II, AFP-L3, alpha 
fucosidase and glypican. (Refer to Section 2.4). Out of all AFP is most widely stud-
ied. In a study evaluating the biomarkers AFP had the best area under the receiver 
operating characteristic curve (0.80, 95% confidence interval [CI]: 0.77–0.84), 
followed by des-gamma carboxy-prothrombin (DCP) (0.72, 95% CI: 0.68–0.77) and 
lectin-bound AFP (AFP-L3%) (0.66, 95% CI: 0.62–0.70) for early-stage HCC and the 
sensitivity of AFP was 66% [83]. As a serological test alone for surveillance AFP has 
suboptimal performance however, it may used if ultrasound is not easily available 
[84, 85]. One problem with use of AFP as surveillance test is that only in 10–20% of 
early HCC have elevated AFP and on the other hand AFP can be falsely elevated in 
chronic hepatitis B and C infections [24]. Instead of single biomarker for surveillance 
combination of multiple biomarkers are being increasingly studied. GALAD, which 
includes gender, age, lectin-bound AFP % (AFPL3%), AFP, and des-gamma car-
boxy prothrombin (DCP) studied in a multinational phase II study involving 6,834 
patients (2,430 HCC and 4,404 chronic liver disease), achieved sensitivities ranging 
from 60–80% for early HCC detection. Another panel including AFP, fucosyl-
ated kininogen, age, gender, alkaline phosphatase, and alanine aminotransferase 
demonstrated a c-statistic of 0.97 (95% CI 0.95–0.99) for early HCC detection. A 
methylated DNA marker panel had a c-statistic of 0.96 (95% CI 0.93–0.99), with 
a sensitivity exceeding 90%, for early HCC detection in a phase II study. Although 
these studies appear promising further research is needed in this field [3].
3.2.3 Combination of both
Meta-analysis had shown that combination of AFP and USG to be superior to 
only USG or AFP alone. Ultrasound with vs. without AFP detected early-stage HCC 
with 63% sensitivity (95% CI, 48–75%) and 45% sensitivity (95% CI, 30–62%), 
respectively (P = .002) [86]. The benefit of AFP in addition to ultrasound was 
consistent across subgroups, including prospective studies, studies conducted in the 
United States, and studies conducted after the year 2000 [86]. Counter argument to 
this approach is that, although addition of AFP to USG helps in detection of 6–8% 
additional tumors does not balance the increase in false positive results resulting 
due to active inflammation causing raise in AFP levels in absence of HCC, adding to 
cost of screening without significant benefit [24].
3.3 Surveillance interval
It depends on rate of tumor growth and incidence of cancer in the population [24]. 
Median doubling time of an HCC lesion is 6.5 months +/− 5.7 months [87]. Analysis of 
prospectively maintained multi-center Italian database showed a better overall median 
survival of 40.3 months in the 6-monthly surveillance group, compared to 30 months 
in the 12-monthly surveillance group (P = 0.03) [88]. Subsequently a French study 
evaluated impact of shortening of surveillance to 3 months. It showed that 3-months 
surveillance group had higher incidence of non-malignant lesions, similar number of 
patients in both 3-months and 6-months group were detected with HCC at an early 
stage (79% vs. 71%; P = 0.40) and similar proportions received curative therapies (62% 
vs. 58%; P = 0.88) [89]. Hence it appears that 6 months interval is optimal.
3.4 Benefits of surveillance
Cancer surveillance programs are aimed to detect tumors early so that curative 





























EASL AASLD APASL JSH INASL
Target 
population
• Cirrhotic Child A and B
• Child C listed for 
transplant
• Noncirrhotic
• HBV high risk for HCC
• Noncirrhotic F3 fibrosis 
as per risk
• All cirrhotic patients
• HCV cirrhotic post antivi-
rals SVR achieved.
• Cirrhosis any etiology.
• Chronic HBV and HCV infec-
tion with high risk.
• Extremely high risk: Cirrhosis 
related HBV and HCV
• High risk:  Cirrhosis nonviral, 
Chronic hepatitis B and C
• Child A and B 
cirrhotics
• Child C cirrhotics on 
transplant list
• High risk noncirrhotic 
chronic HBV and HCV
Ultrasound ✓ ✓ ✓ ✓ ✓
CT/MRI X X X ✓
In extremely high risk group 6–12 
monthly.
X
AFP X ✓+/− ✓
Cut-off 200 ng/ml
✓ ✓





6 months 6 months 6 months Extremely high risk-
3–4 monthly.
High risk − 6 months
6 months
Table 6. 
Recommendations, screening tests, screening interval by various societies across the world. (SVR-sustained virological response).
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in HCC has remained controversial. One randomized controlled trial support-
ing HCC surveillance with 6-monthly abdominal ultrasound was performed in 
more than 18,000 Chinese patients and showed a 37% reduction in mortality risk 
in screened patients [90]. Other studies are retrospective, observational and has 
suffered some biases. Lead time which means the given proportion of survival 
benefit is due to early diagnosis due to surveillance and length time bias arises 
due to detection of slow growing tumors during surveillance programs where as 
fast growing tumors become symptomatic early in their course [3]. Surveillance 
programs can create a state of anxiety in mind of patients. Additional tests and 
financial burden if screening tests are indeterminate. There is also possibility of 
overtreatment of tumor which might never become symptomatic [3]. Considering 
dismal prognosis of HCC, all societies recommend screening of at risk patients for 
HCC [24, 33, 91–93].
3.5 Summary of recommendations by various societies
Table 6 summarizes recommendations, screening tests, screening interval by 
various societies across the world [24, 33, 91–93].
4. Role of multidisciplinary team in surveillance and diagnosis of HCC
Optimal care of patients with HCC involves specialists from multiple disci-
plines like gastroenterology/hepatology, surgical oncologist, liver transplant team, 
medical oncologist, radiologist, interventional radiologist, primary care physician, 
radiation oncologist, pathologists, palliative care specialist, nursing staff and 
dieticians. Multidisciplinary teams (MDTs) have evolved to facilitate care coordina-
tion, reassessments of clinical course, and fine changes in treatment plans required 
for these complex group of patients. MDTs provide platform to facilitate prompt 
diagnosis of HCC by reviewing patients imaging, tumor markers and also assessing 
the need for biopsy which is associated with complications like bleeding and needle 
track seeding. As mentioned in previous sections, diagnosis of HCC is primarily 
based on imaging and there are restricted indications for biopsy of lesion. Experts 
in MDTs can also play a role in suggesting next investigation if one of the diagnostic 
investigation is inconclusive [94].
5. Conclusion
To conclude, small HCC rarely become symptomatic. HCC can be a cause for 
new onset decompensation. Diagnosis of HCC requires multiphase computed 
tomography or MRI scan. In cirrhotic liver, diagnosis of HCC is based on typical 
imaging features and rarely needs biopsy. In noncirrhotic liver and vascular liver 
diseases biopsy may be required to confirm diagnosis. Contrast enhanced ultra-
sound and MRI with hepatobiliary contrast agents are promising modalities for 
evaluation of small and indeterminate nodules. Tumor markers play adjunct role 
in diagnosis but has prognostic significance. Pathologically HCC is heterogenous 
tumor with multiple subtypes with distinct molecular signatures. HCC surveil-
lance in high risk groups with biannual ultrasound with or without alfa-fetoprotein 
helps in early detection of lesions which are amenable to curative treatment. 
Multidisciplinary teams provide platform for care coordination, reassessments of 
clinical course, and fine changes in treatment plans required for this complex group 
of patients.
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